相关实验视频

Updated: Jul 8, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

m6A阅读器IGF2BP2通过稳定DPP4在乳头甲状腺癌中的淋巴转移促进了淋巴转移

Wenlong Wang^1,2, Ying Ding^3,4,5, Yunzhe Zhao⁶

¹Department of General Surgery, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China.

Cancer gene therapy

|December 15, 2023

概括

胰岛素样生长因子2mRNA结合蛋白2 (IGF2BP2) 通过N6-甲基氨酸 (m6A) 修改稳定DPP4,促进乳头甲状腺癌 (PTC) 淋巴转移,提供新的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

淋巴结转移 (LNM) 是乳头甲状腺癌 (PTC) 复发的主要驱动因素.
在PTC中LNM背后的精确分子机制尚未完全理解.
N6-甲基氨酸 (m6A) RNA修饰与癌症进展和转移有关.

研究的目的:

研究IGF2BP2在PTC淋巴结转移中的作用.
阐明潜在的分子机制,包括m6A修饰的参与.
探索在PTC中准IGF2BP2的治疗影响.

主要方法:

人类m6A表谱微阵列,m6ARNA免疫沉降 (MeRIP) 和RNA免疫沉降 (RIP) 测试.
在IGF2BP2敲击后进行体外细胞增殖和入侵试验.
在体内研究评估IGF2BP2对淋巴转移的影响.
分析IGF2BP2对思柏林敏感性的影响.

主要成果:

IGF2BP2表达在PTC中升高,与LNM正相关.
在IGF2BP2的淘汰下,抑制了PTC细胞的增殖,入侵和体内淋巴转移.
IGF2BP2通过以m6A依赖的方式增强DPP4稳定性来激活NF-κB通路.
IGF2BP2调节影响了PTC细胞对西斯普拉丁治疗的敏感性.

结论:

通过依赖m6A的机制稳定DPP4,IGF2BP2促进皮皮性甲状腺癌的淋巴转移.
IGF2BP2代表了抑制PTC转移的潜在治疗标.
这项研究为PTC中m6A介导的淋巴转移调节提供了新的见解.

更多相关视频

Induction and Analysis of Epithelial to Mesenchymal Transition

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...